Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug
Executive Summary
CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.
You may also be interested in...
Cash Runways Dry Up, Creating A ‘Complex’ Road Ahead For Biotech
More than half of emerging biotech companies have less than two years of cash to fund operations, according to EY’s Beyond Borders report.
VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
VistaGen Hopes To Bounce Back With Spray-Based Depression Drug
NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.